Frankenfield Christopher James

Chief Financial Officer at XLO

Sold, on record
$11k
Dollars the filings state
Form 4 sales
2
Latest Jan 2, 2026
Form 144 notices
0
Proposed sales
Companies
1
Filed as an executive or holder

Companies

  • XLOXilio Therapeutics, Inc.Chief Financial Officer

Sales by reason

2
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, every sale on record.

Sales chart range

Timeline

  1. 1 Form 4 sale XLORoutine
    Jan 2, 2025 2025

    Sold 6,954 shares at $0.98 ($7k)

    Frankenfield Christopher James, Chief Financial Officer

    10b5-1 planSold 35.9% of holdings ($19k position)12,421 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale XLORoutine
    Jan 2, 2026 +365 days

    Sold 7,030 shares at $0.64 ($4k)

    Frankenfield Christopher James, Chief Financial Officer

    10b5-1 planSold 22.1% of holdings ($20k position)24,766 shares leftFiling

Every transaction

Loading transactions…

Sales and notices (2)

Form 144 notices and Form 4 sales by Frankenfield Christopher James
Source
Jan 2, 2026Jan 5, 2026XLOChief Financial OfficerForm 4 sale7,030$4k22.1%RoutineSEC
Jan 2, 2025Jan 3, 2025XLOChief Financial OfficerForm 4 sale6,954$7k35.9%RoutineSEC